schizophrenia
Conditions
Interventions
Schizophrenia group:Continuous treatment with national paliperidone palmitate injection
Sponsors
Chaohu Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Outpatients or inpatients with schizophrenia meeting ICD-10/11 diagnostic criteria; (2) Aged 18-65 years (including the lower boundary value), with no gender restriction; (3) Subjects or their guardians sign an informed consent form
Exclusion criteria
Exclusion criteria: (1) Patients have a diagnosis of a psychiatric disorder other than schizophrenia; (2) Those with severe somatic diseases, mental retardation, mental disorders due to organic brain and somatic diseases, or other indicators of abnormality (AST/ALT = 2 times the upper limit of normal value, Cr > 1.2 times the upper limit of normal value, and QTc intervals > 450ms in men and > 470ms in women); (3) Those with a history of psychoactive substance abuse (other than tobacco) in the past 12 months, significant suicidal or violent behaviour; (4) Those with a history of or current delayed dyskinesia (TD), antipsychotic-induced malignant syndrome (NMS), or severe extrapyramidal adverse effects; (5) Those who have had a previous allergic reaction to any antipsychotic drug; (6) Those who have failed previous treatment with risperidone or paliperidone; (7) Pregnant or breastfeeding women or those who plan to become pregnant; or those who cannot be assured of effective contraception for the duration of the study; (8) Any other condition that, in the opinion of the investigator, makes the patient unsuitable for clinical research
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical symptoms;Adverse reaction; | — |
Countries
China
Contacts
Public ContactHuanzhong Liu
Chaohu Hospital of Anhui Medical University
Outcome results
None listed